← Back to screener

Travere Therapeutics, Inc. TVTX

Rank #2512 · Nasdaq · $4.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
10.3
P/E
-42.1
P/B
109.35
ROE
-260.0%
Op. Margin
-267.2%
Debt Ratio
1249%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -42.1x, P/B 109.35x. Ranks in the top 83% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -260.0%. Ranks in the top 96% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 1249%. Ranks in the top 95% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆
Excellent

Revenue growth of 32.7% year over year. Ranks in the top 11% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B–$-0.0B$-0.0B––
2012––$-0.0B$-0.0B–-104
2013–$-0.0B$-0.0B$-0.0B–-1081
2014–$-0.0B$-0.0B$-0.0B–-7490
2015–$-0.0B$-0.0B$-0.0B–-5068
2016–$-0.1B$-0.1B$-0.0B–-1079
2017–$-0.1B$0.1B$-0.0B–-584
2018$0.1B$-0.1B$-0.0B$0.3B-43.676
2019$0.2B$-0.1B$-0.1B$0.3B-34.7127
2020$0.2B$-0.1B$-0.1B$0.3B-48.7131
2021$0.2B$-0.1B$-0.1B$0.3B-78.3125
2022$0.2B$-0.2B$-0.2B$0.2B-88.8215
2023$0.1B$-0.2B$-0.2B$0.2B-151.3298
2024$0.1B$-0.3B$-0.3B$0.3B-292.2195
2025$0.1B$-0.4B$-0.1B$0.0B-267.21249

← See the full screener